Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05844514

COlorectal BReath Analysis (COBRA2)

Sponsor: Imperial College London

View on ClinicalTrials.gov

Summary

Colorectal cancer (CRC) is the second most common cause of cancer death in the United Kingdom, with approximately 17,000 deaths per year. The five-year survival rate from CRC is only 10% when discovered at a late stage, but exceeds 90% if diagnosed early. Symptoms related to CRC can be non-specific, therefore the decision to refer for a colonoscopy can be challenging. There is a clear need to improve earlier detection of CRC so that patients with CRC can be identified earlier and faster, enabling them to start treatment more quickly. The study team is developing a non-invasive breath test that detects small molecules called volatile organic compounds (VOCs) that are specific to CRC. For patients with non-specific symptoms, this test would help GPs to identify those patients that may have underlying CRC, who would benefit from referral for specialised CRC tests.

Official title: The COlorectal BReath Analysis (COBRA2) Study: Non-invasive Breath Testing to Detect Colorectal Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

720

Start Date

2022-09-23

Completion Date

2026-12-01

Last Updated

2025-06-13

Healthy Volunteers

Yes

Interventions

DIAGNOSTIC_TEST

Breath test

Patients must be fasted for a minimum of 4-6 hours prior to breath sample collection. For patients undergoing colonoscopy or surgery, breath samples must be obtained prior to patients receiving bowel preparation in either outpatient clinic or pre-assessment clinic.

Locations (5)

Chelsea and Westminster Hospital

London, United Kingdom

Royal Marsden Hospital

London, United Kingdom

St Mark's Hospital

London, United Kingdom

St Mary's Hospital

London, United Kingdom

West Middlesex University Hospital

London, United Kingdom